Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
The monthly injectable regimen comprising the INSTI* cabotegravir and the NNRTI** rilpivirine long-acting (CAB+RPV LA) maintained virological suppression (ie, plasma HIV-1 RNA <50 copies/mL) in almost all participants of the phase III ATLAS*** trial who entered the extension phase, according to the 96-week analysis presented at HIV Glasgow 2020.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.
Switching to a single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains virologic suppression over 72 weeks in older people living with HIV (PLWH), according to a study presented at the HIV Glasgow 2020 Congress.
An oral lead-in (OLI) regimen consisting of cabotegravir + rilpivirine (CAB+RPV) did not seem to have an effect on HIV patients who switched from a daily oral dolutegravir/abacavir/lamivudine (ABC/DTG/3TC) regimen to a monthly injectable CAB+RPV long-acting (LA) therapeutic regimen, given the similar efficacy, safety, and tolerability profiles observed with or without OLI, according to the 124-week results of the phase III FLAIR* trial presented at HIV Glasgow 2020.